Researchers find Ebola 'Achilles heel' — study | Inquirer Technology

Researchers find Ebola ‘Achilles heel’ — study

/ 07:22 AM May 27, 2015

Ebola

This undated file image made available by the Centers for Disease Control (CDC) shows the Ebola virus. AP FILE PHOTO

WASHINGTON, United States – US researchers believe they may have pinpointed the Achilles heel of the Ebola virus, which could hold the key to developing an effective preventative vaccine, a study reported Tuesday.

Research published in the latest issue of mBio, the online journal of the American Society for Microbiology, said scientists believed a protein called Niemann-Pick C1 (NPC1) was critical for Ebola to infect a host.

Article continues after this advertisement

“Our study reveals NPC1 to be an Achilles heel for Ebola virus infection,” said co-study leader Kartik Chandran, associate professor of microbiology and immunology at the Albert Einstein College of Medicine at Yeshiva University.

FEATURED STORIES

READ: Sierra Leone official: Ebola worst could be over

There are currently no federally approved treatments for Ebola in the United States, and all of the therapies in development elsewhere are designed to attack the virus.

Targeting NPC1 is the first host-based therapeutic approach to combat the disease, which claimed thousands of lives during a devastating outbreak in West Africa last year, the worst in history.

Article continues after this advertisement

Previous in vitro studies had shown that Ebola enters host cells by binding directly to NPC1 and that blocking the virus’s ability to latch on to the protein prevented infection.

Article continues after this advertisement

To see whether this process was repeated in living organisms, investigators exposed three different kinds of mice to the disease — normal mice, mice which had been genetically engineered to be completely deficient in NPC1 and mice engineered to have both a normal and a mutant NPC1 level.

Article continues after this advertisement

While normal mice died from Ebola infection after nine days, mice deficient in NPC1 were completely free of the virus.

“Mice lacking both copies of the NPC1 gene, and therefore devoid of the NPC1 protein, were completely resistant to infection,” Chandran said.

Article continues after this advertisement

“NPC1 is absolutely essential for in vivo pathogenesis, and if you can disrupt this, there are no signs of Ebola virus replication or pathogenesis,” added Andrew Herbert, senior research scientist in the Viral Immunology Branch at the US Army Medical Research Institute of Infectious Diseases in Maryland.

RELATED STORIES

British scientists trial 15-minute Ebola test in Guinea

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

When to wear protective gear

TOPICS: ebola, Research
TAGS: ebola, Research

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.